Overview

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-Label, multicenter, Phase III study.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Treatments:
Gefitinib